Nomura Securities Starts Intercept Pharmaceuticals (ICPT) at Neutral

June 26, 2014 7:54 AM EDT Send to a Friend
Nomura Securities initiates coverage on Intercept Pharmaceuticals (NASDAQ: ICPT) with a Neutral rating and a price target of $294.00.Analyst M ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login